Treatment of Desmoplastic Sarcoma

Surgical Management of Dermatofibrosarcoma Protuberans (DFSP)

The National Comprehensive Cancer Network recommends surgery with complete margin assessment as the definitive treatment for DFSP, with Mohs micrographic surgery or peripheral and deep en face margin assessment (PDEMA) preferred over wide local excision 1
Excision with Mohs or PDEMA is recommended over wide local excision to achieve complete histologic assessment of all margins 1
En face sectioning is preferred to prevent missing small foci of tumor 1
When anatomic structures at the deep margin preclude complete evaluation, use Mohs/PDEMA to evaluate as much of the marginal surface as feasible 1
Wide undermining is discouraged prior to margin confirmation due to risk of concealing residual tumor below mobilized tissue 1
Re-resection until margins are clear or surgery is no longer possible 2, 1
If re-resection is not feasible, consider radiation therapy (5,000-6,000 cGy for close-to-positive or positive margins in 200-cGy fractions per day, with fields extending 3-5 cm beyond surgical margin when clinically feasible) 2
Multidisciplinary consultation for consideration of radiation therapy or other therapy when margins remain positive 1

Imatinib mesylate is indicated for unresectable disease or when unacceptable functional/cosmetic outcomes would occur with surgery 2
Tumors lacking the t(17;22) translocation may not respond to imatinib; molecular analysis using cytogenetics may be useful before institution of therapy 2

If fibrosarcomatous transformation (FS-DFSP) is identified, refer to a center with soft tissue sarcoma expertise 1
FS-DFSP carries significantly higher risks: local recurrence, metastasis, and death compared to conventional DFSP 1
Metastatic risk range for FS-DFSP is 10%-23.5% 1
Multidisciplinary consultation for consideration of further treatment and surveillance including CT of draining nodal basin and chest 1

Clinical follow-up of the primary site every 6-12 months with rebiopsy of any suspicious regions 2
Patient education about regular self-examination 2

Active surveillance ("watch and wait") for 1-2 years is the preferred front-line approach for newly diagnosed desmoid-type fibromatosis, given the unpredictable natural history with possible spontaneous regression and lack of metastatic potential 3, 4, 5, 6
Watch and wait for 1-2 years with close monitoring (MRI every 3 months in first year, then every 6 months up to fifth year) 5, 6
Treatment is reserved for progressing cases, ideally after three consecutive progressions if clinically feasible 6
Exceptions requiring earlier intervention: potentially life-threatening extra-abdominal locations and intra-abdominal desmoids (mesenteric fibromatosis) 3, 4

Abdominal wall: Surgery or medical therapy (or radiation therapy); then medical therapy if progression 6
Intra-abdominal: Medical therapy first-line; surgery if operable; radiation therapy or surgery + radiation therapy for further progression 6
Retroperitoneal/pelvic: Medical therapy first-line; radiation therapy for progression; surgery with additional radiation therapy if considered 6
Extremity/girdles/chest wall: Medical therapy or isolated limb perfusion (if confined to extremity) 6
Head & neck/intrathoracic: Surgery (if morbidity is limited) or radiation therapy 6

Anti-hormonal agents (tamoxifen) as first medical treatment due to limited toxicity, though response rates are low 5
Low-dose chemotherapy with methotrexate and/or vinblastine/vinorelbine for hormonal therapy failure or aggressively growing tumors 5
Tyrosine kinase inhibitors (imatinib) induce sustained progression arrest in 60%-80% with response rates of 6%-16% 5
Sorafenib has shown 18% response rate and 70% disease stabilization rate 5
Conventional dose anthracycline-based chemotherapy if more rapid response is desired (e.g., intra-abdominal or head and neck locations) 5
Pegylated liposomal doxorubicin has significant activity with acceptable toxicity and less cardiac toxicity 5

Post-operative radiation has not demonstrated conclusive benefit after first surgery regardless of margins 5
Adjuvant radiotherapy may reduce recurrence risk after incomplete surgical resection, particularly in recurrent tumors 5

In patients with extensive, inoperable, symptomatic intra‑abdominal desmoid fibromatosis, medical therapy should be initiated as first‑line treatment, specifically low‑dose chemotherapy with methotrexate and vinblastine. 7, 8
The European consensus algorithm explicitly recommends medical therapy as the first‑line option for intra‑abdominal desmoid locations. 7
Persistent pain caused by intra‑abdominal desmoids is identified as a criterion that mandates treatment rather than observation. 7, 8

Start methotrexate 30 mg/m² plus vinblastine 6 mg/m² administered weekly (or every 14 days if better tolerated). 7, 8

Tamoxifen shows low response rates and no clear correlation between tumor size reduction and symptom improvement; therefore a general recommendation for tamoxifen cannot be made. 8
Imatinib yields only 6–16 % objective response rates despite achieving disease stabilization in 60–80 % of patients. 7, 8
Sorafenib provides an 18 % response rate, comparable to imatinib. 7
Tyrosine‑kinase inhibitors are typically reserved for cases where hormonal therapy fails or after low‑dose chemotherapy has been tried. 7

Conventional‑dose anthracycline‑based chemotherapy should be considered when rapid tumor shrinkage is required (e.g., severe pain or threat to vital structures). 7, 8
Pegylated liposomal doxorubicin is preferred in young patients because it markedly reduces cardiac toxicity compared with conventional doxorubicin. 7, 8
The anthracycline regimen is given for 6–8 cycles until the maximum tolerated dose is reached. 7

Surgery is not recommended because the tumor is classified as inoperable. 7
Radiation therapy is reserved for disease progression after failure of medical therapy in the intra‑abdominal setting. 7